Ginkgo Bioworks Holdings Inc - Class A

NYSE: DNA
$0.87
-$0.04 (-4.6%)
Closing price April 17, 2024
Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel therapeutics, food ingredients, and sustainable chemicals that traditionally come from petroleum. Their innovative platform caters to a diverse range of industries including pharmaceuticals, biotechnology, agriculture, food and nutrition, as well as government and defense sectors. Founded in 2008, Ginkgo Bioworks is at the forefront of using biology to improve the world in multiple facets.
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Tuesday's additional top analyst upgrades and downgrades were on Bank of New York Mellon, Butterfly Network, Etsy, Ginkgo Bioworks, Illumina, Poshmark and more.
Wednesday’s additional top analyst upgrades and downgrades included Canadian National Railway, Carrier Global, Century Aluminum, Expedia, Ginkgo Bioworks, U.S. Foods, Visa, Welltower and more.
Wednesday's top analyst upgrades and downgrades included Adobe, Amazon.com, Carnival, Chewy, Fiserv, Ginkgo Bioworks, Global Payments, Nvidia, Oracle, Procter & Gamble, SentinelOne, Walmart and...
Thursday's top analyst upgrades and downgrades included Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV and SoFi...
Tuesday afternoon's top analyst upgrades and downgrades included Coupa Software, Ginkgo Bioworks, Enterprise Products Partners and Intuit.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 2.1 million shares of Ginkgo Bioworks on January 6.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 750,000 shares of Ginkgo Bioworks on December 14.
A couple of Cathie Wood's ARK Invest exchange-traded funds bought nearly 1.5 million shares of Ginkgo Bioworks on December 1.
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 8 million shares of Ginkgo Bioworks on October 6.